Clinical Trial Details
— Status: Completed
Administrative data
NCT number |
NCT05527977 |
Other study ID # |
22060905-IRB01 |
Secondary ID |
|
Status |
Completed |
Phase |
N/A
|
First received |
|
Last updated |
|
Start date |
September 26, 2022 |
Est. completion date |
October 1, 2023 |
Study information
Verified date |
January 2024 |
Source |
Rush University Medical Center |
Contact |
n/a |
Is FDA regulated |
No |
Health authority |
|
Study type |
Interventional
|
Clinical Trial Summary
Clinical documentation which omits significant medical details negatively affects
communication among physicians and impedes the diagnostic process. Clinical documentation may
be improved by using compensation incentives. Therefore, compensation incentives are a
compelling mechanism to promote documentation of significant medical details to improve the
diagnostic process.
The investigators' proposed project will use physician compensation incentives to improve
documentation of clinically significant details for six common diagnoses in outpatient
general internal medicine. The investigators will choose clinically significant details which
more accurately represent patient complexity, improve the diagnostic process, and have
potential to improve patient outcomes. To determine whether compensation incentives improve
documentation of clinically significant details, the investigators will compare physicians'
baseline documentation to incentivized documentation. The purpose of the investigators'
project is to improve communication of clinically significant diagnostic information among
physicians, thereby reducing suboptimal treatment plans, overuse, medical error, and
cognitive burden upon physicians.
Description:
Implementation: The investigators' proposed project will use physician compensation
incentives to improve documentation of clinically significant details for six common
diagnoses in outpatient general internal medicine. The purpose of the program is to improve
clinical documentation in order to reduce misdiagnosis and medical errors. The investigators
will invite 30-35 primary care physicians in internal medicine and family medicine within
Rush University Medical Group to participate. The investigators will review participants'
office visit notes for clinical documentation that meets pre-specified criteria. The
investigators anticipate that physicians will receive a $5-$10 compensation bonus for each
office visit progress note that meets clinical criteria. The investigators' program will be
in effect for 3-months. The average performing physician is expected to receive $650-$700 in
compensation incentives over the entire 3-month period (higher performing physicians expected
to earn $1,000 or above for superior performance).
Approach: To determine whether compensation incentives improve documentation of clinically
significant details, the investigators will compare physicians' baseline documentation
(during a 6-week run-in period) to incentivized documentation (a 3-month period when
physicians will receive compensation incentives for their clinical documentation). Two
research assistants will perform retrospective chart review and audits of office visit
progress notes. Notes will be scored for whether documentation includes pre-specified
clinically significant information. For example, if a patient has had a Deep Vein Thrombosis
(DVT), the investigators would assess whether the month of onset of the DVT and duration of
anticoagulation therapy was documented in the note. The investigators anticipate that
compensation incentives will improve physicians' clinical documentation of clinically
significant medical details. The investigators' results will be reported in aggregate at the
physician-level.
Participation: 30-35 physicians will be invited to participate in both the incentives program
and analysis comparing baseline performance to incentivized performance. If a physician opts
out of the analysis, that participant will not be eligible for compensation incentives. The
investigators chose a sample of 30-35 physicians so that the study has enough power to detect
a significant difference in performance in clinical documentation during the incentivized
period compared to baseline.
Risks to patients: The investigators will use patient-level data as covariates in the
analysis. The investigators' analysis will occur in a similar fashion as other retrospective
studies, whereby patient-level information will be used from individual office visits in the
analysis. Patient-level information will be de-identified as quickly as possible and
precautions will be made to keep patient and physician-level data secure.